1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 5
FEATURED COMPANIES
- Adamis Pharmaceuticals
- ALK-Abelló
- Antares Pharma
- Emerade
- Hospira
- Impax Laboratories
- MORE
About epinephrine autoinjector
Epinephrine is among the first line of treatment drugs for anaphylactic conditions and is considered a life-saving drug during emergencies. Epinephrine autoinjectors have proved to be a life savior for people with severe allergies from as early as the 1980s. The global epinephrine autoinjector market has been witnessing continuous technological innovations and developments over the years, after the first FDA approval of EpiPen in 1987.
The analysts forecast the global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global epinephrine autoinjector market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of various epinephrine autoinjectors to key end-users such as hospitals, clinics, and individuals.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
The report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
Key vendors
- ALK-Abelló
- Impax Laboratories
- Lincoln Medical
- Mylan
Other prominent vendors
- Adamis Pharmaceuticals
- Antares Pharma
- Emerade
- Hospira
- Kaleo Pharma
- Teva Pharmaceutical Industries
Market drivers
- Increasing prevalence of allergies
- For a full, detailed list, view the full report
Market challenges
- Product recalls and regulatory issues
- For a full, detailed list, view the full report
Market trends
- Tentative product launches
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Epinephrine is among the first line of treatment drugs for anaphylactic conditions and is considered a life-saving drug during emergencies. Epinephrine autoinjectors have proved to be a life savior for people with severe allergies from as early as the 1980s. The global epinephrine autoinjector market has been witnessing continuous technological innovations and developments over the years, after the first FDA approval of EpiPen in 1987.
The analysts forecast the global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global epinephrine autoinjector market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of various epinephrine autoinjectors to key end-users such as hospitals, clinics, and individuals.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
The report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
Key vendors
- ALK-Abelló
- Impax Laboratories
- Lincoln Medical
- Mylan
Other prominent vendors
- Adamis Pharmaceuticals
- Antares Pharma
- Emerade
- Hospira
- Kaleo Pharma
- Teva Pharmaceutical Industries
Market drivers
- Increasing prevalence of allergies
- For a full, detailed list, view the full report
Market challenges
- Product recalls and regulatory issues
- For a full, detailed list, view the full report
Market trends
- Tentative product launches
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Adamis Pharmaceuticals
- ALK-Abelló
- Antares Pharma
- Emerade
- Hospira
- Impax Laboratories
- MORE
PART 01: Executive summary
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Epinephrine autoinjector: Overview
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by dosage
Global epinephrine autoinjector market by 0.15gm dosage
Global epinephrine autoinjector market by 0.30gm dosage
Global epinephrine autoinjector market by 0.5gm dosage
PART 07: Market segmentation by age group
PART 08: Market segmentation by end-user
Hospitals and clinics
Individuals
PART 09: Geographical segmentation
Epinephrine autoinjector market in the Americas
Epinephrine autoinjector market in EMEA
Epinephrine autoinjector market in APAC
PART 10: Market drivers
Increasing prevalence of allergies
Technological advances
Marketing strategies
PART 11: Impact of drivers
PART 12: Market challenges
Product recalls and regulatory issues
Presence of substitutes
High cost
PART 13: Impact of drivers and challenges
PART 14: Market trends
Tentative product launches
Growing awareness about epinephrine autoinjectors
Patient assistance programs
PART 15: Vendor landscape
Competitive scenario
Key news
Geographical presence of key vendors
PART 16: Key vendor analysis
ALK-Abelló
Impax Laboratories
Lincoln Medical
Mylan
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: About the Author
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global epinephrine autoinjector market: Analysis
Exhibit 03: Key buying criteria for epinephrine autoinjectors
Exhibit 04: Buying criteria for epinephrine autoinjectors
Exhibit 05: Key factors influencing development of epinephrine autoinjectors
Exhibit 06: Allergy statistics
Exhibit 07: Market overview: Global epinephrine autoinjector market
Exhibit 08: Global epinephrine autoinjector market ($ millions)
Exhibit 09: Global epinephrine autoinjector market analysis: Developed and developing markets
Exhibit 10: Five forces analysis
Exhibit 11: Global epinephrine autoinjector market segmentation by dosage 2016
Exhibit 12: Global epinephrine autoinjector market segmentation by dosage 2020
Exhibit 13: Global epinephrine autoinjector market by 0.15gm dosage 2016-2021 ($ millions)
Exhibit 14: Global epinephrine autoinjector market by 0.30gm dosage 2016-2021 ($ millions)
Exhibit 15: Global epinephrine autoinjector market by 0.5gm dosage 2016-2021 ($ millions)
Exhibit 16: Global epinephrine autoinjector market segmentation by dosage 2016-2021 (%)
Exhibit 17: Global epinephrine autoinjector market segmentation by dosage 2016-2021 ($ millions)
Exhibit 18: Global epinephrine autoinjector market by age group 2016
Exhibit 19: Global epinephrine autoinjector market by end-user 2016
Exhibit 20: Global epinephrine autoinjector market segmentation by geography 2016
Exhibit 21: Global epinephrine autoinjector market segmentation by geography 2021
Exhibit 22: Epinephrine autoinjector market in the Americas 2016-2021 ($ millions)
Exhibit 23: Market overview: Americas
Exhibit 24: Epinephrine autoinjector market overview: US
Exhibit 25: Epinephrine autoinjector market in the US 2016-2021 ($ millions)
Exhibit 26: Market overview: EMEA
Exhibit 27: Epinephrine autoinjector market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market overview: APAC
Exhibit 29: Epinephrine autoinjector market in APAC 2016-2021 ($ millions)
Exhibit 30: Global epinephrine autoinjector market segmentation by geography 2016-2021 ($ millions)
Exhibit 31: Global epinephrine autoinjector market segmentation by geography 2016-2021 (%)
Exhibit 32: Allergy statistics
Exhibit 33: Technological advances
Exhibit 34: Marketing strategies of Mylan
Exhibit 35: Impact of drivers
Exhibit 36: Product recalls
Exhibit 37: Alternatives of epinephrine autoinjectors in the market
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Competitive structure of the global epinephrine autoinjector market
Exhibit 40: Market penetration of various epinephrine autoinjector manufacturers globally (2016)
Exhibit 41: Strategic success factors of companies in global epinephrine autoinjector market 2016
Exhibit 42: Share of vendors in global epinephrine autoinjector market 2016
Exhibit 43: Regional analysis of key vendors
Exhibit 44: Key highlights of ALK-Abelló
Exhibit 45: ALK-Abelló strength assessment
Exhibit 46: ALK-Abelló strategy assessment
Exhibit 47: ALK-Abelló opportunity assessment
Exhibit 48: Key highlights of Impax Laboratories
Exhibit 49: Impax Laboratories strength assessment
Exhibit 50: Impax Laboratories strategy assessment
Exhibit 51: Impax Laboratories opportunity assessment
Exhibit 52: Lincoln Medical strength assessment
Exhibit 53: Lincoln Medical strategy assessment
Exhibit 54: Lincoln Medical opportunity assessment
Exhibit 55: Key highlights of Mylan
Exhibit 56: Mylan strength assessment
Exhibit 57: Mylan strategy assessment
Exhibit 58: Mylan opportunity assessment
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Epinephrine autoinjector: Overview
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by dosage
Global epinephrine autoinjector market by 0.15gm dosage
Global epinephrine autoinjector market by 0.30gm dosage
Global epinephrine autoinjector market by 0.5gm dosage
PART 07: Market segmentation by age group
PART 08: Market segmentation by end-user
Hospitals and clinics
Individuals
PART 09: Geographical segmentation
Epinephrine autoinjector market in the Americas
Epinephrine autoinjector market in EMEA
Epinephrine autoinjector market in APAC
PART 10: Market drivers
Increasing prevalence of allergies
Technological advances
Marketing strategies
PART 11: Impact of drivers
PART 12: Market challenges
Product recalls and regulatory issues
Presence of substitutes
High cost
PART 13: Impact of drivers and challenges
PART 14: Market trends
Tentative product launches
Growing awareness about epinephrine autoinjectors
Patient assistance programs
PART 15: Vendor landscape
Competitive scenario
Key news
Geographical presence of key vendors
PART 16: Key vendor analysis
ALK-Abelló
Impax Laboratories
Lincoln Medical
Mylan
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: About the Author
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global epinephrine autoinjector market: Analysis
Exhibit 03: Key buying criteria for epinephrine autoinjectors
Exhibit 04: Buying criteria for epinephrine autoinjectors
Exhibit 05: Key factors influencing development of epinephrine autoinjectors
Exhibit 06: Allergy statistics
Exhibit 07: Market overview: Global epinephrine autoinjector market
Exhibit 08: Global epinephrine autoinjector market ($ millions)
Exhibit 09: Global epinephrine autoinjector market analysis: Developed and developing markets
Exhibit 10: Five forces analysis
Exhibit 11: Global epinephrine autoinjector market segmentation by dosage 2016
Exhibit 12: Global epinephrine autoinjector market segmentation by dosage 2020
Exhibit 13: Global epinephrine autoinjector market by 0.15gm dosage 2016-2021 ($ millions)
Exhibit 14: Global epinephrine autoinjector market by 0.30gm dosage 2016-2021 ($ millions)
Exhibit 15: Global epinephrine autoinjector market by 0.5gm dosage 2016-2021 ($ millions)
Exhibit 16: Global epinephrine autoinjector market segmentation by dosage 2016-2021 (%)
Exhibit 17: Global epinephrine autoinjector market segmentation by dosage 2016-2021 ($ millions)
Exhibit 18: Global epinephrine autoinjector market by age group 2016
Exhibit 19: Global epinephrine autoinjector market by end-user 2016
Exhibit 20: Global epinephrine autoinjector market segmentation by geography 2016
Exhibit 21: Global epinephrine autoinjector market segmentation by geography 2021
Exhibit 22: Epinephrine autoinjector market in the Americas 2016-2021 ($ millions)
Exhibit 23: Market overview: Americas
Exhibit 24: Epinephrine autoinjector market overview: US
Exhibit 25: Epinephrine autoinjector market in the US 2016-2021 ($ millions)
Exhibit 26: Market overview: EMEA
Exhibit 27: Epinephrine autoinjector market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market overview: APAC
Exhibit 29: Epinephrine autoinjector market in APAC 2016-2021 ($ millions)
Exhibit 30: Global epinephrine autoinjector market segmentation by geography 2016-2021 ($ millions)
Exhibit 31: Global epinephrine autoinjector market segmentation by geography 2016-2021 (%)
Exhibit 32: Allergy statistics
Exhibit 33: Technological advances
Exhibit 34: Marketing strategies of Mylan
Exhibit 35: Impact of drivers
Exhibit 36: Product recalls
Exhibit 37: Alternatives of epinephrine autoinjectors in the market
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Competitive structure of the global epinephrine autoinjector market
Exhibit 40: Market penetration of various epinephrine autoinjector manufacturers globally (2016)
Exhibit 41: Strategic success factors of companies in global epinephrine autoinjector market 2016
Exhibit 42: Share of vendors in global epinephrine autoinjector market 2016
Exhibit 43: Regional analysis of key vendors
Exhibit 44: Key highlights of ALK-Abelló
Exhibit 45: ALK-Abelló strength assessment
Exhibit 46: ALK-Abelló strategy assessment
Exhibit 47: ALK-Abelló opportunity assessment
Exhibit 48: Key highlights of Impax Laboratories
Exhibit 49: Impax Laboratories strength assessment
Exhibit 50: Impax Laboratories strategy assessment
Exhibit 51: Impax Laboratories opportunity assessment
Exhibit 52: Lincoln Medical strength assessment
Exhibit 53: Lincoln Medical strategy assessment
Exhibit 54: Lincoln Medical opportunity assessment
Exhibit 55: Key highlights of Mylan
Exhibit 56: Mylan strength assessment
Exhibit 57: Mylan strategy assessment
Exhibit 58: Mylan opportunity assessment
Note: Product cover images may vary from those shown
3 of 5
LOADING...
4 of 5
FEATURED COMPANIES
- Adamis Pharmaceuticals
- ALK-Abelló
- Antares Pharma
- Emerade
- Hospira
- Impax Laboratories
- MORE
New Report Released: – Global Epinephrine Autoinjector Market 2017-2021
The author of the report recognizes the following companies as the key players in the global epinephrine autoinjector market: ALK-Abelló, Impax Laboratories, Lincoln Medical, and Mylan.
Other Prominent Vendors in the market are: Adamis Pharmaceuticals, Antares Pharma, Emerade, Hospira, Kaleo Pharma, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is tentative product launches. The US market is forecasted to witness a number of product launches during the forecast period, due to the increased government's pressure on the FDA to approve more generic products of epinephrine autoinjectors.”
According to the report, one of the major drivers for this market is increasing prevalence of allergies. The prevalence of allergies to food items, food additives, latex, and dust and the associated anaphylaxis has been increasing worldwide. On average, 30-35% of the global population is diagnosed with an allergy annually. This was initially seen in countries such as the UK, other countries in Europe, and the US, but it is now common in all industrially developed countries.
Further, the report states that one of the major factors hindering the growth of this market is product recalls and regulatory issues. The global epinephrine autoinjector market has continuously faced hindrance owing to the periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Mylan monopoly.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global epinephrine autoinjector market: ALK-Abelló, Impax Laboratories, Lincoln Medical, and Mylan.
Other Prominent Vendors in the market are: Adamis Pharmaceuticals, Antares Pharma, Emerade, Hospira, Kaleo Pharma, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is tentative product launches. The US market is forecasted to witness a number of product launches during the forecast period, due to the increased government's pressure on the FDA to approve more generic products of epinephrine autoinjectors.”
According to the report, one of the major drivers for this market is increasing prevalence of allergies. The prevalence of allergies to food items, food additives, latex, and dust and the associated anaphylaxis has been increasing worldwide. On average, 30-35% of the global population is diagnosed with an allergy annually. This was initially seen in countries such as the UK, other countries in Europe, and the US, but it is now common in all industrially developed countries.
Further, the report states that one of the major factors hindering the growth of this market is product recalls and regulatory issues. The global epinephrine autoinjector market has continuously faced hindrance owing to the periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Mylan monopoly.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- ALK-Abelló
- Impax Laboratories
- Lincoln Medical
- Mylan
- Adamis Pharmaceuticals
- Antares Pharma
- Emerade
- Hospira
- Kaleo Pharma
- Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
